Vivos therapeutics, inc. (VVOS) 2025Q4 financial report shows revenue of 3.82M USD, with a YoY growth rate of 3.41%. This figure indicates that Vivos therapeutics, inc. (VVOS)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of Vivos therapeutics, inc. (VVOS)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.